Compare iShares China Large-Cap ETF (FXI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares China Large-Cap ETF trades at $33.93 (market cap $3.86B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: iShares China Large-Cap ETF is the larger of the two by market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 16,323,837). Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 149 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| FXI | RXRX | |
|---|---|---|
Market Cap | $3.86B | $2.14B |
Volume | 16,323,837 | 30,789,535 |
52-Week High | $41.08 | $6.79 |
52-Week Low | $31.59 | $2.84 |
Typical Hold Time | 149 Days | 22 Days |
Sector | — | Health |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI, the iShares China Large-Cap ETF, trades at $33.42, down 1.04% with bearish technical signals from moving averages. The ETF faces headwinds from China's economic challenges and trade tensions, though it trades at a significant discount to U.S. equities with a P/E of 11.10 versus the S&P 500's 22.54. Recent geopolitical developments from the Trump-Xi summit and China's export dynamics create mixed sentiment.
The outlook remains cautious with technical indicators signaling selling pressure, while fundamental valuation appears attractive for risk-tolerant investors seeking China exposure. Key risks include ongoing U.S.-China tensions, China's industrial overcapacity, and weak domestic consumption that could limit upside potential despite the valuation discount.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
